Stifel's Benjamin Burnett gives his take on biotech and discusses Iovance, Cabaletta, Arcellx, Revolution, Fate, CRISPR, and Disc.

Co-Founder and CEO Alex Aravanis describes how epigenentic engineering could have advantages over gene editing.

Stéphane Bancel talks about Moderna's programs for COVID, RSV, CMV, cancer, and more.

John Maraganore shares his thoughts about biotech's big achievements in 2023 and what to watch in 2024.

Ethan Perlstein describes the past and present of his rare diseases-focused company Perlara

Chris Garabedian's thoughts on the IPO market, products vs platforms, and more discipline and prioritization in biotech.

Robert Blum describes Aficamten’s topline safety, efficacy, and how the company views its competitive profile.

Sri Kosuri describes how Octant is using advances in biology, chemistry, multiplexing, and computing to create its platform.

Co-Founder & CEO Ashley Zehnder describes how Fauna studies animals that have disease resistance to help tackle human disease.

Stephen Dilly describes how Codexis is trying help RNA companies use enzymes to more efficiently make oligonucleotides.

Co-Founders Serge Saxonov and Ben Hindson give us a corporate overview and demonstrate the Chromium single cell platform.

Jory Bell and Nate Chang describe Playground Global's philosophy of investing in life sciences and assisting entrepreneurs.

Thomas Butler describes Biomea's hypothesis of utilizing a covalent, irreversible menin inhibitor to promote beta cell proliferation.

Apple Tree Partner and Deep Apple CEO Spiros Liras describes how the company aims to leverage virtual screening and machine learning.

Liisa Bayko talks about yesterdays pain data and also recent news from Alnylam, Altimmune, Caribou Biosciences, Insmed, and AN2 Therapeutics

The UC Berkeley professor and Innovative Genomics Institute director talks about the diseases that might be treated with gene editing.

Celine Halioua describes how Loyal is trying to extend the lifespan of dogs, and explains recent FDA feedback.

Syndax's CEO reviews late breaking data on the menin inhibitor revumenib in KMT2A-rearranged leukemias and discusses axatilimab's GvHD data.

Brian Goff highlights data from the phase 2 portion of the RISE UP pivotal study of Mitapivat for SCD that was presented at #ASH23 today.